What is the idea behind combining AOD-9604 with CJC-1295?

AOD-9604 targets fat breakdown directly without raising IGF-1, while CJC-1295 raises overall GH output. Pairing them aims to layer a focused lipolytic effect on top of a broader GH-driven metabolic increase.

Is there strong evidence the blend outperforms either alone?

No. The combination is based on mechanistic rationale; controlled human trials directly validating the blend's superiority are lacking, and AOD-9604's own fat-loss evidence is modest.

← All peptides

Weight & Metabolic

Growth Hormone Secretagogues

Research Chemical

AOD-9604 + CJC Blend

Also known as: AOD-9604 + CJC Blend, Fat Loss GH Stack

A combination pairing the fat-loss GH fragment AOD-9604 with the GHRH analog CJC-1295, studied to layer direct lipolytic activity onto elevated endogenous growth hormone.

Mechanism of Action

This blend combines AOD-9604, the lipolytic C-terminal fragment of GH that stimulates fat breakdown via beta-3 adrenergic signaling without raising IGF-1, with CJC-1295, a GHRH-receptor agonist that increases endogenous GH and IGF-1. The rationale is to pair a targeted fat-mobilizing peptide with an overall increase in GH-driven metabolism. The two address fat loss through partly overlapping but distinct routes.

Half-life: Combined: AOD-9604 ~30 min; CJC-1295 no-DAC ~30 min or DAC ~days
Administration Routes: subcutaneous
Research Status: Research Chemical